Form 4: Leap Therapeutics Director Joseph Loscalzo Acquires Stock Options

Director Joseph Loscalzo acquired 25,000 stock options in Leap Therapeutics, Inc. on October 2, 2024.

Summary

• Joseph Loscalzo, a director of Leap Therapeutics, Inc., acquired 25,000 stock options on October 2, 2024.
• The options have an exercise price of $2.45.
• The options were granted under Leap's 2022 Equity Incentive Plan, as amended.
• The options vest in four quarterly installments starting December 31, 2024, and ending September 30, 2025, contingent on continued service as a director, consultant, or service provider.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing detailing stock option grants, which is neither inherently positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedule implies continued involvement of the director with the company.

Industry Context

This filing is a routine disclosure related to insider transactions, common in publicly traded companies. It provides transparency regarding the compensation and equity ownership of company directors.

Comparison to Industry Standards

• Stock option grants are a common form of executive compensation in the biotechnology industry, used to align the interests of management with those of shareholders.
• The vesting schedule of the options is typical, with quarterly installments over a defined period.

Stakeholder Impact

• The stock option grant could have a minor positive impact on shareholder sentiment, as it indicates that a director has a vested interest in the company's success.

Key Dates